A detailed history of Stifel Financial Corp transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 161,978 shares of RXRX stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
161,978
Previous 108,875 48.77%
Holding current value
$1.01 Million
Previous $816,000 30.76%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $314,369 - $456,685
53,103 Added 48.77%
161,978 $1.07 Million
Q2 2024

Aug 13, 2024

BUY
$7.35 - $10.05 $473,825 - $647,883
64,466 Added 145.16%
108,875 $816,000
Q1 2024

May 13, 2024

BUY
$9.13 - $15.52 $157,218 - $267,254
17,220 Added 63.33%
44,409 $442,000
Q4 2023

Feb 12, 2024

BUY
$5.09 - $10.79 $138,392 - $293,369
27,189 New
27,189 $268,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.12B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.